Scienture, BlinkRx announce strategic collaboration to expand access to Arbli [Yahoo! Finance]
Scienture Holdings, Inc. (SCNX)
Company Research
Source: Yahoo! Finance
Arbli is expected to be available on the BlinkRx platform in Q1 2026. With BlinkRx, 52% more patients start therapy and remain on their medication 40% longer as prescribed. “Arbli represents a meaningful advancement for patients who need a ready-to-use oral suspension of losartan potassium,” commented Narasimhan Mani, President and co-CEO of Scienture. “BlinkRx removes friction in the patient journey, from reducing administrative barriers and accelerating therapy initiation to improving adherence, which translates into greater prescription volume, longer duration on therapy, lower access costs, and broader patient affordability and reach.” Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now Se
Show less
Read more
Impact Snapshot
Event Time:
SCNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCNX alerts
High impacting Scienture Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
SCNX
News
- SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan PotassiumGlobeNewswire
- Scienture Holdings, Inc. (SCNX) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
- Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 [Yahoo! Finance]Yahoo! Finance
- SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025GlobeNewswire
SCNX
Sec Filings
- 11/18/25 - Form 8-K
- 11/14/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- SCNX's page on the SEC website